sTRAIL在肝炎肝硬化和原发性肝癌患者血清中的表达及与肝损伤指标关系的临床研究  

Research on sTRAIL and cirrhosis of liver and primary hepatic cellular carcinoma of HBV infection in human

作　　者：岳凤娥[1] 宋修光[1] 杜文军[1] 张利宁[2] 

机构地区：[1]济南市传染病医院内科,山东济南250021 [2]山东大学医学院免疫教研室,山东济南250012

出　　处：《肿瘤防治杂志》2005年第4期255-256,267,共3页China Journal of Cancer Prevention and Treatment

基　　金：济南市卫生局课题资助

摘　　要：目的:探索可溶性肿瘤细胞坏死因子相关凋 亡诱导配体(sTRAIL)在HBV感染人体所致的肝炎肝 硬化、原发性肝癌发病机制中的作用。方法:采用 ELISA法检测50例肝炎肝硬化、原发性肝癌患者血清 sTRAIL水平。结果:正常人血清sTRAIL的水平为 813.08±273.85;肝炎肝硬化患者血清sTRAIL的水平 为1238.76±257.95,与正常人比较,P<0.001;原发性 肝癌患者的血清sTRAIL的水平为1172.07±224.97 与正常人比较,P<0.001。肝炎肝硬化、原发性肝癌患 者血清sTRAIL与其肝功能指标相关性分析:sTRAIL 与ALT呈正相关,r=0.731(0.702),P<0.001,与AST 呈正相关,r=0.826(0.674),P<0.001。原发性肝癌患 者的血清sTRAIL与其TBIL不相关,r=0.428,P> 0.5;与A不相关,r=0.078、P>0.5。结论:sTRAIL诱 导细胞凋亡是肝细胞损伤机制之一。OBJECTIVE： To explode the mechanism of sTRAIL （soluble TRAIL） in the pathogenesis of cirrhosis of liver and primary hepatic cellular carcinoma of HBV infection in human. METHODS： sTRAIL in 50 patients＇ serum were examined with ELISA. RESULTS： The levels of sTRAIL in patients＇ cirrhosis of liver as well as primary hepatic cellular carcinoma were higher than that in normal persons. In cirrhosis of liver and primary hepatic cellular carcinoma, sTRAIL level was positively correlated with ALT, AST. In primary hepatic cellular carcinoma, sTRAIL level was not correlated with serum albumin and TBIL. CONCLUSION：The results indicated higher level of sTRAIL expression is related with liver damage and apoptosis is one of the mechanisms for liver damage in HBV infection.

关 键 词：肝硬化/病因学 肝肿瘤/病因学 肿瘤坏死因子 脱噬作用 肝炎病毒 乙型 

分 类 号：R735.7[医药卫生—肿瘤]